Filed by Eidos Therapeutics, Inc.
Pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934
Subject Company: Eidos Therapeutics, Inc.
Commission File No.: 001-38533
The following are excerpts from Eidos Therapeutics, Inc.s press release reporting third quarter 2020 results, issued on October 29, 2020
On October 5, 2020, Eidos entered into an agreement and plan of merger providing for the acquisition by BridgeBio Pharma, Inc.
(BridgeBio) of all of the outstanding common stock of Eidos it does not already own.
[...]
On October 5, 2020, Eidos entered into an agreement and plan of merger with BridgeBio, Globe Merger Sub I, Inc., an indirect wholly-owned subsidiary of
BridgeBio, and Globe Merger Sub II, Inc., an indirect wholly-owned subsidiary of BridgeBio, providing for the acquisition by BridgeBio of all of the outstanding common stock of Eidos it does not already own, representing approximately 36.3% of the
outstanding shares of Eidos common stock. Pursuant to the merger agreement, Eidos stockholders will have the right to receive in the transaction, at their election, either 1.85 shares of BridgeBio common stock or $73.26 in cash per Eidos share upon
the closing of the transaction, subject to proration to ensure that the aggregate amount of cash consideration is no greater than $175 million. Upon closing of the transaction and subject to the terms of the merger agreement, Eidos will become
an indirect wholly-owned subsidiary of BridgeBio, and Eidos common stock will cease to trade on the NASDAQ Global Select Market. The transaction is subject to the receipt of stockholder approvals and the satisfaction or waiver of other
customary closing conditions. Closing is expected to occur in the first quarter of 2021 subject to the satisfaction or waiver of such closing conditions.
In connection with the execution of the merger agreement, Eidos also entered into voting agreements with members of BridgeBios board of directors and
KKR Genetic Disorder L.P., collectively owning approximately 36% of BridgeBios outstanding common stock, pursuant to which they agreed, among other things, to vote their shares in favor of the issuance of BridgeBios common stock in
connection with the transactions contemplated under the merger agreement.
The foregoing descriptions of the merger agreement and the voting agreements do
not purport to be complete and are qualified in their entirety by reference to the full text of the merger agreement, a form of the voting agreements entered into by the BridgeBio directors party thereto and the voting agreement entered into by KKR
Genetic Disorder L.P., copies of which were filed as Exhibit 2.1, Exhibit 2.2 and Exhibit 2.3, respectively, to Eidos Form 8-K filed with the Securities and Exchange Commission, or SEC, on
October 7, 2020.